Study to Evaluate How Patients Regard the Benefits and Risks of Low-dose Aspirin for the Prevention of Heart and Blood Vessels Disease and for the Prevention of Cancer of the Colon and Rectum

Overview

Research shows that low-dose Aspirin prevents diseases of heart and blood vessels as well as cancer of the colon and rectum and it is also associated with risk of bleeding. In this study, they want to learn how patients regard the benefits and risks of low-dose Aspirin for the prevention of these diseases. The researchers also want to learn how patients balance these risks and benefits.

Full Title of Study: “Patient-centred Benefit-risk Observational Study of Low-dose Aspirin for CVD (Cardiovascular Disease) and CRC (Colorectal Cancer) Prevention”

Study Type

  • Study Type: Observational
  • Study Design
    • Time Perspective: Cross-Sectional
  • Study Primary Completion Date: October 14, 2019

Interventions

  • Drug: Acetylsalicylic acid (Aspirin, BAYE4465)
    • This study does not involve prescription of the drugs. This study is a cross-sectional survey of patients taking low-dose aspirin or patients who are eligible but not taking low-dose aspirin.

Arms, Groups and Cohorts

  • Primary prevention
    • Patients in Italy who are eligible to use low-dose aspirin for primary prevention of CVD and CRC. Subgroups: Patients eligible for and using low-dose aspirin who are at 20% ten-year CVD risk for primary prevention of CVD Patients eligible for and not using low-dose aspirin who are at 20% ten-year CVD risk for primary prevention of CVD
  • Secondary prevention
    • Patients in Italy who are eligible to use low-dose aspirin for secondary prevention of CVD and CRC. Subgroups: Patients eligible for and using low-dose aspirin for secondary prevention of CVD Patients eligible for and not using low-dose aspirin for secondary prevention of CVD
  • Physicians
    • Physicians from Italy with experience recommending low-dose aspirin for primary and/or secondary prevention of CVD and CRC.

Clinical Trial Outcome Measures

Primary Measures

  • Perceive of low dose aspirin
    • Time Frame: Up to 1 hour
    • Using qualitative interviews to assess how patients and physicians perceive the benefits and risks of low-dose aspirin for the prevention of cardiovascular disease (CVD) and colorectal cancer (CRC)
  • Patients’ benefit/risk trade-offs
    • Time Frame: Up to 1 hour
    • Using quantitative surveys to elicit patients’ benefit/risk trade-offs on key efficacy and safety outcomes of low-dose aspirin in CVD and CRC prevention

Secondary Measures

  • Change in likelihood of AEs
    • Time Frame: Up to 1 hour
    • Quantify the change in likelihood of adverse events (AEs) that patients are willing to accept in order to experience the benefits of low-dose aspirin for CRC and CVD prevention compared to CVD prevention alone
  • Preferences of aspirin using in different subgroups
    • Time Frame: Up to 1 hour
    • Assess how different subgroups of patients, such as those using low-dose aspirin and those eligible for but not using low-dose aspirin, differ in their preferences

Participating in This Clinical Trial

Patient Eligibility Criteria Inclusion Criteria:

  • Age and CVD characteristics – Primary prevention: – 50-70 years of age – Self-report clinical characteristics that result to 20% or higher, 10-year risk of CVD based on the Progetto Cuore scores – Secondary prevention: – 18 years or older – Having a self-reported history of CV event (e.g., myocardial infarction (MI), ischaemic stroke or Transient Ischaemic stroke, , and angina) – Able to read and understand Italian – No participation in an investigational program with interventions outside of routine clinical practice – For qualitative interviews: – Willing and able to provide (electronic) informed consent to participate in the study – Willing and able to participate in a telephone interview, and to be audio-recorded – For pilot/cognitive interviews : – Willing and able to complete an online survey – Willing and able to provide (electronic) informed consent to participate in the study – Willing and able to participate in an in-person interview, and to be audio-recorded – For quantitative main survey: – Willing and able to complete an online survey – Willing and able to provide (electronic) informed consent to participate in the study Exclusion Criteria:

  • Have glucose-6-phosphate dehydrogenase (G6PD) deficiency (which commonly causes haemolytic anaemia, which is often triggered from eating fava beans, a condition called Favism) – Have the following conditions (which are contraindications to low-dose aspirin) – Known hypersensitivity to salicylates – Known to have had asthma induced by salicylates – Having been diagnosed with acute gastroduodenal ulcers – Haemorrhagic diathesis – Renal failure – Hepatic failure – Concomitant treatment with methotrexate – Cognitive impairment, hearing difficulty, visual impairment, acute psychopathology, or insufficient knowledge of Italian that-in the opinion of the investigator/interviewer-could interfere with a patient's ability to provide written consent and complete an interview or survey – To be currently pregnant – Are pharmaceutical company employees or employed in a position where they have a direct role in treating patients with CVD Physician Eligibility Criteria: – A medically trained physician – Able to read, speak, and understand Italian sufficiently to complete an interview – Able to provide informed consent electronically – Have at least five year experience prescribing low-dose aspirin for primary and secondary prevention of CVD – Willing to be audio-recorded, including adherence to the interview instructions

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: 70 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Bayer
  • Provider of Information About this Clinical Study
    • Sponsor

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.